Cancer Gene Therapy
ISSN 0929-1903 · Springer Nature · United States · active 1992–2026
Metrics
“Cites per paper” is a two-year cited-by rate computed from OpenAlex. It is not a Clarivate Journal Impact Factor — we neither compute nor license that metric. Citation rates differ enormously between fields, so compare within a discipline.
Indexing & access
Access status: unknown. Where this comes from publisher-level signals rather than works-level data it is a heuristic — confirm on the journal’s own site, especially regarding any article processing charge.
Scope
Frequently asked
Is Cancer Gene Therapy a predatory journal?
Our screening does not flag Cancer Gene Therapy. That is not a guarantee of quality — it means the venue is not on Beall's archive (frozen since 2017) and does not match our name-pattern heuristic. It is listed in Scopus, Web of Science, PubMed, which is a positive signal.
Is Cancer Gene Therapy indexed in Scopus or Web of Science?
Per our venue index, Cancer Gene Therapy appears in: Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.
What is Cancer Gene Therapy's impact?
Papers in Cancer Gene Therapy are cited about 6.0 times each within two years of publication, and Scimago places it in Q1, with an h-index of 111. This is not a Clarivate Journal Impact Factor — we neither compute nor license that metric — and a citation rate is a property of a field as much as of a journal.
Is Cancer Gene Therapy open access?
We hold no reliable open-access classification for Cancer Gene Therapy. Check the journal's own site for its access model and any article processing charge.